应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
III 信息服务
盘后交易 07-17 18:46:12 EDT
4.68
-0.06
-1.27%
盘后
4.77
+0.09
+1.92%
18:38 EDT
最高
4.78
最低
4.67
成交量
14.79万
今开
4.74
昨收
4.74
日振幅
2.32%
总市值
2.26亿
流通市值
1.60亿
总股本
4,820万
成交额
69.68万
换手率
0.43%
流通股本
3,422万
市净率
2.37
ROE
8.09%
每股收益
0.16
52周最高
5.28
52周最低
2.95
市盈率
29.89
股息
0.18
股息收益率
0.04
ROA
3.30%
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
港股异动 | 康方生物(09926)午前涨超10% 依沃西疗法一线治疗结直肠癌III期临床首例患者入组
智通财经 · 03:36
港股异动 | 康方生物(09926)午前涨超10% 依沃西疗法一线治疗结直肠癌III期临床首例患者入组
索尼发布黑卡RX1R III全画幅旗舰相机,售价33999元
IT之家 · 07-15 14:20
索尼发布黑卡RX1R III全画幅旗舰相机,售价33999元
复宏汉霖(02696):HLX22联合疗法III期试验在美完成首例患者给药
智通财经 · 07-14
复宏汉霖(02696):HLX22联合疗法III期试验在美完成首例患者给药
阿斯利康重磅高血压新药 III 期成功
Insight数据库 · 07-14
阿斯利康重磅高血压新药 III 期成功
微芯生物股价小幅震荡 西达本胺III期临床数据出炉
金融界 · 07-09
微芯生物股价小幅震荡 西达本胺III期临床数据出炉
微芯生物(688321.SH):西达本胺一线治疗弥漫大B细胞淋巴瘤的III期临床试验获顶线分析数据
智通财经 · 07-09
微芯生物(688321.SH):西达本胺一线治疗弥漫大B细胞淋巴瘤的III期临床试验获顶线分析数据
信息服务盘中异动 股价大涨5.00%报5.25美元
市场透视 · 07-08
信息服务盘中异动 股价大涨5.00%报5.25美元
基石药业-B(02616)公布Nofazinlimab治疗肝细胞癌的国际多中心 III期研究的最新进展
智通财经 · 07-04
基石药业-B(02616)公布Nofazinlimab治疗肝细胞癌的国际多中心 III期研究的最新进展
【安科生物成立新公司,含远程健康管理服务业务】 公开资料显示,近日,温州育高儿科诊所有限公司成立,法定代表人为杨钧,注册资本为200万元,经营范围包含:医疗服务;非急救转运服务;食品销售;药品零售;医疗器械互联网信息服务;远程健康管理服务;保健用品销售等。股权数据显示,该公司由安科生物间接全资持股。
金融界 · 07-04
【安科生物成立新公司,含远程健康管理服务业务】 公开资料显示,近日,温州育高儿科诊所有限公司成立,法定代表人为杨钧,注册资本为200万元,经营范围包含:医疗服务;非急救转运服务;食品销售;药品零售;医疗器械互联网信息服务;远程健康管理服务;保健用品销售等。股权数据显示,该公司由安科生物间接全资持股。
港股异动 | 再鼎医药(09688)涨超4% 宣布贝玛妥珠单抗用于FGFR2b阳性一线胃癌III期研究数据取得阳性结果
智通财经 · 07-03
港股异动 | 再鼎医药(09688)涨超4% 宣布贝玛妥珠单抗用于FGFR2b阳性一线胃癌III期研究数据取得阳性结果
【中设股份在无锡成立低空智能科技公司】公开资料显示,近日,江苏中设集团(无锡)低空智能科技有限公司成立,法定代表人为夏至,经营范围包含:人工智能应用软件开发;地理遥感信息服务;信息系统集成服务等。股权数据显示,该公司由中设股份全资持股。
金融界 · 07-03
【中设股份在无锡成立低空智能科技公司】公开资料显示,近日,江苏中设集团(无锡)低空智能科技有限公司成立,法定代表人为夏至,经营范围包含:人工智能应用软件开发;地理遥感信息服务;信息系统集成服务等。股权数据显示,该公司由中设股份全资持股。
【卓创资讯:目前尚未参与稳定币相关项目】卓创资讯在互动平台表示,公司从事大宗商品信息服务,目前尚未参与稳定币相关项目。
金融界 · 07-02
【卓创资讯:目前尚未参与稳定币相关项目】卓创资讯在互动平台表示,公司从事大宗商品信息服务,目前尚未参与稳定币相关项目。
福建东捷铭信息服务有限公司成立,注册资本1000万人民币
金融界 · 07-01
福建东捷铭信息服务有限公司成立,注册资本1000万人民币
G-III服装集团盘中异动 股价大涨5.04%报23.53美元
市场透视 · 07-01
G-III服装集团盘中异动 股价大涨5.04%报23.53美元
再鼎医药盘前涨超4% 贝玛妥珠单抗III期胃癌达到主要终点
金吾资讯 · 07-01
再鼎医药盘前涨超4% 贝玛妥珠单抗III期胃癌达到主要终点
每月 1 次口服!默沙东启动 HIV 预防新药 III 期临床
Insight数据库 · 07-01
每月 1 次口服!默沙东启动 HIV 预防新药 III 期临床
信息服务6月30日成交额为156.46万美元
市场透视 · 07-01
信息服务6月30日成交额为156.46万美元
华熙生物:送检润百颜紧致充盈次抛精华液样品,重组III型胶原蛋白原料添加量符合规范
市场资讯 · 07-01
华熙生物:送检润百颜紧致充盈次抛精华液样品,重组III型胶原蛋白原料添加量符合规范
Krystal生物技术公司在KB803的III期IOLITE试验中为首位患者给药Krystal Biotech Doses First Patient in Phase III IOLITE Trial for KB803
动脉网 · 06-30
Krystal生物技术公司在KB803的III期IOLITE试验中为首位患者给药Krystal Biotech Doses First Patient in Phase III IOLITE Trial for KB803
信息服务6月27日成交额为212.54万美元
市场透视 · 06-28
信息服务6月27日成交额为212.54万美元
加载更多
公司概况
公司名称:
信息服务
所属市场:
NASDAQ
上市日期:
2007-02-12
主营业务:
Information Services Group, Inc.于2006年7月20日在特拉华州注册成立。该公司是一家全球领先的技术研究和咨询公司。ISG是超过900家客户、超过75家百强企业值得信赖的商业伙伴,致力于帮助企业、公共部门组织以及服务和技术提供商实现卓越运营和更快增长。该公司专门从事数字化转型服务,包括自动化、云和数据分析;采购咨询;托管治理和风险服务;网络载体服务;技术战略和运营设计;变革管理;市场情报和技术研究与分析。
发行价格:
--
{"stockData":{"symbol":"III","market":"US","secType":"STK","nameCN":"信息服务","latestPrice":4.68,"timestamp":1752782400000,"preClose":4.74,"halted":0,"volume":147871,"hourTrading":{"tag":"盘后","latestPrice":4.77,"preClose":4.68,"latestTime":"18:38 EDT","volume":2653,"amount":12416.728984099998,"timestamp":1752791886054},"delay":0,"floatShares":34215567,"shares":48204172,"eps":0.156567,"marketStatus":"盘后交易","change":-0.06,"latestTime":"07-17 18:46:10 EDT","open":4.74,"high":4.78,"low":4.67,"amount":696772.8838719999,"amplitude":0.023207,"askPrice":5.18,"askSize":100,"bidPrice":4.55,"bidSize":90,"shortable":3,"etf":0,"ttmEps":0.156567,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1752796800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1171256400000,"exchange":"NASDAQ","adjPreClose":4.74,"dividendRate":0.038462,"preHourTrading":{"tag":"盘前","latestPrice":4.74,"preClose":4.74,"latestTime":"09:26 EDT","volume":1225,"amount":5838.929425,"timestamp":1752758810026},"postHourTrading":{"tag":"盘后","latestPrice":4.77,"preClose":4.68,"latestTime":"18:38 EDT","volume":2653,"amount":12416.728984099998,"timestamp":1752791886054},"volumeRatio":0.722724,"impliedVol":1.3929,"impliedVolPercentile":0.88},"requestUrl":"/m/hq/s/III","defaultTab":"news","newsList":[{"id":"2552117748","title":"港股异动 | 康方生物(09926)午前涨超10% 依沃西疗法一线治疗结直肠癌III期临床首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2552117748","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552117748?lang=zh_cn&edition=full","pubTime":"2025-07-17 11:36","pubTimestamp":1752723365,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,康方生物午前涨超10%,截至发稿,涨10.24%,报138.9港元,成交额15.06亿港元。消息面上,7月16日,据康方生物官微消息,康方生物自主研发的全球首创PD-1/VEGF双特异性抗体新药依达方用于一线治疗晚期转移性结直肠癌的注册性III期临床研究已完成首例患者入组。注册性III期研究AK112-312/HARMONi-GI6的启动,将进一步验证依沃西联合化疗在该患者群体中的优越性,有望成为MSS/pMMR型mCRC患者全新且高效的一线免疫治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1318850.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","IE00B5MMRT66.SGD","LU1720050803.USD","IE00B543WZ88.USD","LU0417516571.SGD","BK4134","LU1794554557.SGD","BK1574","BK1161","LU0348783233.USD","IE00BPRC5H50.USD","LU2488822045.USD","LU0348784397.USD","09926"],"gpt_icon":0},{"id":"2551311914","title":"索尼发布黑卡RX1R III全画幅旗舰相机,售价33999元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551311914","media":"IT之家","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551311914?lang=zh_cn&edition=full","pubTime":"2025-07-15 22:20","pubTimestamp":1752589212,"startTime":"0","endTime":"0","summary":"索尼黑卡 RX1R III 搭载约 6100 万有效像素的 35mm 全画幅 Exmor R CMOS 背照式影像传感器,并采用索尼新一代 BIONZ XR 影像处理器,配备经典的固定式蔡司 Sonnar T* 35mm F2 定焦镜头,每台相机经过微米级高精度镜片组调整,以配合影像传感器实现惊人的画质表现。索尼黑卡 RX1R III 采用的蔡司经典 Sonnar T* 35mm F2 定焦镜头,同样具备优异的光学性能。索尼黑卡全画幅旗舰 RX1R III 和相关配件将于 2025 年 7 月下旬上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8l18puLytdP","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["BK4588","BK4078","BK4554","SONY","BK4571","III","BK4585","BK4577","BK4604","LU0154236417.USD","BK4134"],"gpt_icon":0},{"id":"2551901335","title":"复宏汉霖(02696):HLX22联合疗法III期试验在美完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2551901335","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551901335?lang=zh_cn&edition=full","pubTime":"2025-07-14 17:08","pubTimestamp":1752484126,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复宏汉霖(02696)发布公告,近日,一项HLX22(重组人源化抗 HER2单克隆抗体注射液)(“HLX22”)联合曲妥珠单抗和化疗(XELOX)对比曲妥珠单抗和化疗(XELOX)联合或不联合帕博利珠单抗一线治疗人类表皮生长因子受体2(HER2)阳性局部晚期或转移性胃食管交界部和胃癌的国际多中心3期临床研究已完成美国首例患者给药。该3期临床研究亦正于中国境内(不包括中国港澳台地区,下同)、澳大利亚及日本等国家/地区同步开展中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1317374.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02696","III","BK4134"],"gpt_icon":0},{"id":"2551723469","title":"阿斯利康重磅高血压新药 III 期成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2551723469","media":"Insight数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551723469?lang=zh_cn&edition=full","pubTime":"2025-07-14 14:32","pubTimestamp":1752474726,"startTime":"0","endTime":"0","summary":"7 月 14 日,阿斯利康宣布,Baxdrostat 在针对未控制或难治性高血压患者的BaxHTN III 期临床试验中,达到了主要终点和所有次要终点。2023 年 2 月,阿斯利康 18 亿美元收购CinCor,囊获了该产品。目前,Baxdrostat 正在开展高血压、心力衰竭等多个适应症的临床。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714143828a44921de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714143828a44921de&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AZN","LU0320765992.SGD","LU0109394709.USD","LU2417539215.USD","BK4007","BK4568","BK4588","LU0889565916.HKD","BK4134","LU1829250122.USD","BK4585","LU2456880835.USD","LU2462157665.USD","LU2236285917.USD","III"],"gpt_icon":0},{"id":"2550657788","title":"微芯生物股价小幅震荡 西达本胺III期临床数据出炉","url":"https://stock-news.laohu8.com/highlight/detail?id=2550657788","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550657788?lang=zh_cn&edition=full","pubTime":"2025-07-10 01:53","pubTimestamp":1752083586,"startTime":"0","endTime":"0","summary":"截至2025年7月9日15时,微芯生物股价报31.30元,较前一交易日下跌0.32%,成交额达6.18亿元。7月9日,微芯生物公告称,其自主研发的西达本胺针对一线治疗弥漫大B细胞淋巴瘤的关键性III期临床试验获得最终结果的顶线分析数据,试验组无事件生存期显著优于对照组,达到主要研究终点。公司表示,正在准备该适应症的常规批准申报。2025年7月9日,微芯生物主力资金净流入3693.05万元,占流通市值的0.29%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/10015351595901.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["688321","BK4134","III","BK0239"],"gpt_icon":0},{"id":"2550341689","title":"微芯生物(688321.SH):西达本胺一线治疗弥漫大B细胞淋巴瘤的III期临床试验获顶线分析数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2550341689","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550341689?lang=zh_cn&edition=full","pubTime":"2025-07-09 16:02","pubTimestamp":1752048130,"startTime":"0","endTime":"0","summary":"智通财经APP讯,微芯生物 公告,公司自主研发的西达本胺针对一线治疗弥漫大B细胞淋巴瘤关键性III期临床试验已于近日获得最终结果的顶线分析数据,试验组无事件生存期显著优于对照组,达成研究主要终点。西达本胺作用于表观遗传相关靶点组蛋白去乙酰化酶。此次顶线分析中,试验组无事件生存期较对照组展现具统计学显著意义的差异,进一步验证了西达本胺联合方案可为初治MYC和BCL2双表达DLBCL患者带来显著且可持续的疗效,且安全性良好。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1315664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","III","BK1141","688321","BK4134","BK1576","03347","BK1583"],"gpt_icon":0},{"id":"2550521005","title":"信息服务盘中异动 股价大涨5.00%报5.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550521005","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550521005?lang=zh_cn&edition=full","pubTime":"2025-07-09 00:16","pubTimestamp":1751991382,"startTime":"0","endTime":"0","summary":"北京时间2025年07月09日00时16分,信息服务股票出现异动,股价急速拉升5.00%。截至发稿,该股报5.25美元/股,成交量10.6159万股,换手率0.22%,振幅4.90%。信息服务股票所在的信息科技服务行业中,整体涨幅为0.04%。其相关个股中,玖富、CID HoldCo Inc Wt、Global Engine Group Holding Limited涨幅较大,Bigbear.Ai, Inc.、WNS控股、Innodata Inc.较为活跃,换手率分别为45.40%、15.50%、6.73%,振幅较大的相关个股有Global Engine Group Holding Limited、Data Storage Corp C/Wts 18/05/2026 、玖富,振幅分别为19.46%、18.23%、14.58%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709001623a43e6db6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709001623a43e6db6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4134","III"],"gpt_icon":0},{"id":"2548394504","title":"基石药业-B(02616)公布Nofazinlimab治疗肝细胞癌的国际多中心 III期研究的最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2548394504","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548394504?lang=zh_cn&edition=full","pubTime":"2025-07-04 22:34","pubTimestamp":1751639654,"startTime":"0","endTime":"0","summary":"据悉,Nofazinlimab是一种靶向人程序性细胞死亡蛋白1的人源化重组IgG4单克隆抗体,正在开发用于肿瘤的免疫治疗。Nofazinlimab与人类、食蟹猴和小鼠PD-1均具有高亲和力,可阻断 PD-1与PD-L1和PD-L2配体的相互作用。Nofazinlimab已于2020年7月获美国食品药品监督管理局授予孤儿药资格,用于治疗肝细胞癌。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1314299.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02616","III","BK1161","BK1574","BK4134"],"gpt_icon":0},{"id":"2548330921","title":"【安科生物成立新公司,含远程健康管理服务业务】 公开资料显示,近日,温州育高儿科诊所有限公司成立,法定代表人为杨钧,注册资本为200万元,经营范围包含:医疗服务;非急救转运服务;食品销售;药品零售;医疗器械互联网信息服务;远程健康管理服务;保健用品销售等。股权数据显示,该公司由安科生物间接全资持股。","url":"https://stock-news.laohu8.com/highlight/detail?id=2548330921","media":"金融界","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548330921?lang=zh_cn&edition=full","pubTime":"2025-07-04 10:43","pubTimestamp":1751596981,"startTime":"0","endTime":"0","summary":"公开资料显示,近日,温州育高儿科诊所有限公司成立,法定代表人为杨钧,注册资本为200万元,经营范围包含:医疗服务;非急救转运服务;食品销售;药品零售;医疗器械互联网信息服务;远程健康管理服务;保健用品销售等。股权数据显示,该公司由安科生物间接全资持股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/07/04104351476913.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09997","160636","300009","BK0239","BK1574","BK0042","BK0070","159883","BK4134","BK0060","BK1583","159792","BK1222","BK1100","III","09996"],"gpt_icon":0},{"id":"2548384098","title":"港股异动 | 再鼎医药(09688)涨超4% 宣布贝玛妥珠单抗用于FGFR2b阳性一线胃癌III期研究数据取得阳性结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2548384098","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548384098?lang=zh_cn&edition=full","pubTime":"2025-07-03 09:48","pubTimestamp":1751507331,"startTime":"0","endTime":"0","summary":"消息面上,据再鼎医药官微消息,6月30日,再鼎医药宣布,评估贝玛妥珠单抗联合化疗作为一线治疗的III期FORTITUDE-101临床研究在预设的中期分析中达到了其主要终点总生存期。贝玛妥珠单抗已获得中国国家药品监督管理局药品审评中心授予的突破性疗法认定,用于治疗FGFR2b阳性胃癌及胃食管结合部癌。此外,一项贝玛妥珠单抗联合化疗及纳武利尤单抗一线治疗胃癌患者的III期研究也正在进行,数据预计在2025年下半年公布。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1313384.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","ZLAB","BK4588","BK4526","BK4134","09688","BK1574","BK4548","III","BK4585","BK1161","BK1588","BK4531","BK4139"],"gpt_icon":0},{"id":"2548475718","title":"【中设股份在无锡成立低空智能科技公司】公开资料显示,近日,江苏中设集团(无锡)低空智能科技有限公司成立,法定代表人为夏至,经营范围包含:人工智能应用软件开发;地理遥感信息服务;信息系统集成服务等。股权数据显示,该公司由中设股份全资持股。","url":"https://stock-news.laohu8.com/highlight/detail?id=2548475718","media":"金融界","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548475718?lang=zh_cn&edition=full","pubTime":"2025-07-03 09:42","pubTimestamp":1751506970,"startTime":"0","endTime":"0","summary":"公开资料显示,近日,江苏中设集团(无锡)低空智能科技有限公司成立,法定代表人为夏至,经营范围包含:人工智能应用软件开发;地理遥感信息服务;信息系统集成服务等。股权数据显示,该公司由中设股份全资持股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/07/03094251456129.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["002883","BK0221","BK0177","III","BK4134","161631"],"gpt_icon":0},{"id":"2548831577","title":"【卓创资讯:目前尚未参与稳定币相关项目】卓创资讯在互动平台表示,公司从事大宗商品信息服务,目前尚未参与稳定币相关项目。","url":"https://stock-news.laohu8.com/highlight/detail?id=2548831577","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548831577?lang=zh_cn&edition=full","pubTime":"2025-07-02 08:55","pubTimestamp":1751417758,"startTime":"0","endTime":"0","summary":"卓创资讯在互动平台表示,公司从事大宗商品信息服务,目前尚未参与稳定币相关项目。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/07/02085551428081.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["CRCL","BK4023","BK4134","III","BK0231","000979.SH","301299","161715"],"gpt_icon":0},{"id":"2548885238","title":"福建东捷铭信息服务有限公司成立,注册资本1000万人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2548885238","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548885238?lang=zh_cn&edition=full","pubTime":"2025-07-02 00:04","pubTimestamp":1751385842,"startTime":"0","endTime":"0","summary":"天眼查App显示,近日,福建东捷铭信息服务有限公司成立,法定代表人为程奎,注册资本1000万人民币,由厦门旦元碳智能源投资有限公司全资持股。企业名称福建东捷铭信息服务有限公司法定代表人程奎注册资本1000万人民币国标行业信息传输、软件和信息技术服务业>软件和信息技术服务业>软件开发地址厦门市集美区勤学路100-8号501室之十一企业类型法人商事主体营业期限2025-7-1至无固定期限登记机关","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/02000451425302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4134","III"],"gpt_icon":0},{"id":"2548688389","title":"G-III服装集团盘中异动 股价大涨5.04%报23.53美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548688389","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548688389?lang=zh_cn&edition=full","pubTime":"2025-07-01 23:26","pubTimestamp":1751383595,"startTime":"0","endTime":"0","summary":"北京时间2025年07月01日23时26分,G-III服装集团股票出现异动,股价快速拉升5.04%。截至发稿,该股报23.53美元/股,成交量15.1928万股,换手率0.35%,振幅5.60%。机构评级方面,在所有4家参与评级的机构中,25%的券商给予买入建议,50%的券商给予持有建议,25%的券商给予卖出建议。G-III服装集团股票所在的服装制造行业中,整体涨幅为1.17%。G-III服装集团公司简介:G-III Apparel Group Ltd 是一家纺织公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070123263597961064&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070123263597961064&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4202","GIII","III","BK4134"],"gpt_icon":0},{"id":"2548005383","title":"再鼎医药盘前涨超4% 贝玛妥珠单抗III期胃癌达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2548005383","media":"金吾资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548005383?lang=zh_cn&edition=full","pubTime":"2025-07-01 19:12","pubTimestamp":1751368348,"startTime":"0","endTime":"0","summary":"金吾财讯 | 再鼎医药 盘前涨超4%,截至发稿,报36.50美元。消息面上, 中金发布研报称,6月30日,Amgen/再鼎公布Bemarituzumab联合化疗一线治疗FGFR2b阳性胃癌患者III期临床研究中期分析数据,达到了其主要终点总生存期,显示出具有显著统计学意义和临床意义的改善。再鼎拥有该产品大中华区开发和商业化的独家授权。在确保数据安全、合法合规的基础上,探索为创新药研发提供必要的医保数据服务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507011913329795d1a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507011913329795d1a6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4588","ZLAB","LU2488822045.USD","BK4134","BK4139","III","BK4526","BK4548","BK4531"],"gpt_icon":0},{"id":"2548738071","title":"每月 1 次口服!默沙东启动 HIV 预防新药 III 期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2548738071","media":"Insight数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548738071?lang=zh_cn&edition=full","pubTime":"2025-07-01 16:50","pubTimestamp":1751359851,"startTime":"0","endTime":"0","summary":"当地时间 6 月 29 日,默沙东在ClinicalTrials.gov 官网上登记了一项评估每月一次口服 MK-8527 用于 HIV-1 暴露前预防有效性和安全性的 III 期临床试验(MK-8527-011)。来源:ClinicalTrials.gov 官网这是一项随机、双盲、活性药物对照的 III 期临床研究,计划入组4390 名受试者,纳入标准如下图所示。来源:ClinicalTrials.gov 官网","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701165647a7280e09&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701165647a7280e09&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1571399168.USD","LU2361044865.SGD","SG9999014559.SGD","III","SG9999002232.USD","IE00BJT1NW94.SGD","LU2023250843.SGD","LU1699723380.USD","BK4134","IE00BSNM7G36.USD","LU2361045086.USD","SG9999001176.SGD","BK4559","LU0106261372.USD","IE0002141913.USD","LU2112291526.USD","MRK","LU1069347547.HKD","BK4007","SG9999014542.SGD","SG9999001440.SGD","SG9999013999.USD","LU0006306889.USD","BK4533","IE00B1BXHZ80.USD","LU0289739699.SGD","LU1116320901.HKD","LU1989771016.USD","LU2089984988.USD","LU0122379950.USD","LU0070302665.USD","LU1037948897.HKD","SGXZ57979304.SGD","LU1037948541.HKD","IE00BBT3K403.USD","LU1983299246.USD","LU2324357040.USD","SG9999014575.USD","LU0266013472.USD","LU1430594728.SGD","IE00B4R5TH58.HKD","LU0265550359.USD","IE000M9KFDE8.USD","SG9999015358.SGD","SG9999014567.USD","IE0009355771.USD","LU0058720904.USD","IE00BLSP4239.USD","LU0098860793.USD","LU0965509101.SGD"],"gpt_icon":0},{"id":"2548102336","title":"信息服务6月30日成交额为156.46万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548102336","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548102336?lang=zh_cn&edition=full","pubTime":"2025-07-01 10:34","pubTimestamp":1751337249,"startTime":"0","endTime":"0","summary":"美东时间2025年6月30日,信息服务成交额为156.46万美元,成交额较昨日减少26.39%,当日成交量为33.27万股。信息服务于2025年6月30日涨3.23%,报4.8美元,该股过去5个交易日涨2.56%,年初至今涨46.88%,过去60日涨20.56%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-06-30|156.46万|-26.39%|33.27万|#|2025-06-27|212.54万|123.08%|45.74万|#|2025-06-26|95.27万|-0.98%|20.54万|#|2025-06-25|96.21万|54.86%|20.36万|#|2025-06-24|62.13万|-13.68%|13.15万|Information Services Group Inc 是一家总部位于美国的技术观点、市场情报和咨询服务公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701103416a72755de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701103416a72755de&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4134","III"],"gpt_icon":0},{"id":"2548047732","title":"华熙生物:送检润百颜紧致充盈次抛精华液样品,重组III型胶原蛋白原料添加量符合规范","url":"https://stock-news.laohu8.com/highlight/detail?id=2548047732","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548047732?lang=zh_cn&edition=full","pubTime":"2025-07-01 09:31","pubTimestamp":1751333460,"startTime":"0","endTime":"0","summary":"由该国家级权威机构出具的详尽报告指出:通过HPLC-HRMS技术,并采用“特征肽段-基质匹配标线法”,经严谨测试,送检润百颜紧致充盈次抛精华液样品中,重组III型胶原蛋白原料的含量测定结果为0.60mg/g。华熙生物强调,该产品中的重组胶原蛋白原料在配方中本来即为微量添加原料,所以添加量符合规范。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/t/2025-07-01/doc-infcxncu3707907.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4134","BK0229","688363","III","BK0239"],"gpt_icon":0},{"id":"2547094059","title":"Krystal生物技术公司在KB803的III期IOLITE试验中为首位患者给药Krystal Biotech Doses First Patient in Phase III IOLITE Trial for KB803","url":"https://stock-news.laohu8.com/highlight/detail?id=2547094059","media":"动脉网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547094059?lang=zh_cn&edition=full","pubTime":"2025-06-30 21:02","pubTimestamp":1751288520,"startTime":"0","endTime":"0","summary":"Primary Endpoint and Study Assessments主要终点和研究评估The primary endpoint of IOLITE is the change in the average number of days per month with corneal abrasion symptoms while receiving KB803 compared to placebo. To account for expected high inter-patient variability, statistical analysis will focus on intra-patient paired measurements. Patients will complete weekly symptom diaries and monthly questionnaires to record corneal abrasion frequency and severity, as well as to capture impressions from patients or caregivers regarding disease changes throughout the study..IOLITE 的主要终点是,在接受 KB803 与安慰剂治疗期间,每月平均出现角膜擦伤症状的天数变化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506302105219794a067&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506302105219794a067&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4134","KRYS","BK4139","III"],"gpt_icon":0},{"id":"2546119773","title":"信息服务6月27日成交额为212.54万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2546119773","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546119773?lang=zh_cn&edition=full","pubTime":"2025-06-28 10:45","pubTimestamp":1751078714,"startTime":"0","endTime":"0","summary":"美东时间2025年6月27日,信息服务成交额为212.54万美元,成交额较昨日增加123.08%,当日成交量为45.74万股。信息服务于2025年6月27日涨0.65%,报4.65美元,该股过去5个交易日涨2.2%,年初至今涨42.29%,过去60日涨19.47%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-06-27|212.54万|123.08%|45.74万|#|2025-06-26|95.27万|-0.98%|20.54万|#|2025-06-25|96.21万|54.86%|20.36万|#|2025-06-24|62.13万|-13.68%|13.15万|#|2025-06-23|71.98万|-32.33%|15.56万|Information Services Group Inc 是一家总部位于美国的技术观点、市场情报和咨询服务公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250628104515a721f230&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250628104515a721f230&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["III","BK4134"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.isg-one.com","stockEarnings":[{"period":"1week","weight":-0.0595},{"period":"1month","weight":-0.0063},{"period":"3month","weight":0.2742},{"period":"6month","weight":0.4813},{"period":"1year","weight":0.3504},{"period":"ytd","weight":0.4192}],"compareEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":0.0357},{"period":"3month","weight":0.1858},{"period":"6month","weight":0.0446},{"period":"1year","weight":0.1051},{"period":"ytd","weight":0.0651}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Information Services Group, Inc.于2006年7月20日在特拉华州注册成立。该公司是一家全球领先的技术研究和咨询公司。ISG是超过900家客户、超过75家百强企业值得信赖的商业伙伴,致力于帮助企业、公共部门组织以及服务和技术提供商实现卓越运营和更快增长。该公司专门从事数字化转型服务,包括自动化、云和数据分析;采购咨询;托管治理和风险服务;网络载体服务;技术战略和运营设计;变革管理;市场情报和技术研究与分析。","yearOnYearQuotes":[{"month":1,"riseRate":0.470588,"avgChangeRate":0.025538},{"month":2,"riseRate":0.529412,"avgChangeRate":0.012941},{"month":3,"riseRate":0.333333,"avgChangeRate":0.043359},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.008159},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.028576},{"month":6,"riseRate":0.5,"avgChangeRate":0.015439},{"month":7,"riseRate":0.444444,"avgChangeRate":0.019247},{"month":8,"riseRate":0.529412,"avgChangeRate":-0.00064},{"month":9,"riseRate":0.411765,"avgChangeRate":-0.011058},{"month":10,"riseRate":0.352941,"avgChangeRate":-0.036309},{"month":11,"riseRate":0.647059,"avgChangeRate":0.057949},{"month":12,"riseRate":0.529412,"avgChangeRate":-0.000919}],"exchange":"NASDAQ","name":"信息服务","nameEN":"Information"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信息服务,III,信息服务股票,信息服务股票老虎,信息服务股票老虎国际,信息服务行情,信息服务股票行情,信息服务股价,信息服务股市,信息服务股票价格,信息服务股票交易,信息服务股票购买,信息服务股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}